Morten Ladekarl
- Oncology top 5%
- Pancreatic and Hepatic Oncology Research 19
- Lung Cancer Research Studies 14
- Cancer Immunotherapy and Biomarkers 11
- Cancer Research top 5%
- Cancer Genomics and Diagnostics 18
- Breast Cancer Treatment Studies 12
- Immunology top 10%
- Neurology top 10%
- Neuroblastoma Research and Treatments 10
- Epidemiology top 10%
- Neuroendocrine Tumor Research Advances 15
-
- Gastric Cancer Management and Outcomes 11
- Co-authors
- Bettina S. NedergaardFrede DonskovAndreas CarusHenrik HagerJens Randel NyengaardFlemming Brandt SørensenJens OvergaardElisabeth I Penninga
- Cited by
- OncologyCancer ResearchImmunology
- Partner nations
- DenmarkUnited StatesNorway
In The Last Decade
Morten Ladekarl
89 papers receiving 1.7k citations
Peers
Comparison fields: 5 of 113
- Oncology 832
- Cancer Research 433
- Immunology 289
- Neurology 194
- Epidemiology 362
Countries citing papers authored by Morten Ladekarl
This map shows the geographic impact of Morten Ladekarl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Morten Ladekarl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Morten Ladekarl more than expected).
Fields of papers citing papers by Morten Ladekarl
This network shows the impact of papers produced by Morten Ladekarl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Morten Ladekarl. The network helps show where Morten Ladekarl may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Morten Ladekarl, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 8 | |
| 2 | 2024 | 2 | |
| 3 | 2023 | 1 | |
| 4 | 2023 | 1 | |
| 5 | 2023 | 11 | |
| 6 | 2023 | 2 | |
| 7 | 2022 | 1 | |
| 8 | 2021 | 32 | |
| 9 | 2021 | 3 | |
| 10 | 2020 | 15 | |
| 11 | 2020 | 14 | |
| 12 | 2020 | 1 | |
| 13 | 2019 | 20 | |
| 14 | 2018 | 10 | |
| 15 | 2017 | 27 | |
| 16 | Danish experiences with FOLFIRINOX as first-line therapy in patients with inoperable pancreatic cancer. | 2014 | 7 |
| 17 | 2011 | 5 | |
| 18 | Influence of fixation, embedding and section mounting on stereological estimates of cancer cell mean volume-weighted nuclear volume | 1996 | 1 |
| 19 | 1995 | 28 | |
| 20 | The prognostic value of quantitative histopathology in breast cancer: results of retrospective studies | 1994 | 2 |
About Morten Ladekarl
Morten Ladekarl is a scholar working on Cancer Research, Oncology and Hepatology, having authored 97 papers that have together received 1.7k indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (19 papers), Cancer Genomics and Diagnostics (18 papers), Neuroendocrine Tumor Research Advances (15 papers), Lung Cancer Research Studies (14 papers), Breast Cancer Treatment Studies (12 papers), Gastric Cancer Management and Outcomes (11 papers), Cancer Immunotherapy and Biomarkers (11 papers) and Neuroblastoma Research and Treatments (10 papers). The work is most often cited by research in Oncology (832 citations), Cancer Research (433 citations) and Immunology (289 citations). Morten Ladekarl has collaborated with scholars based in Denmark, United States and Norway. Frequent co-authors include Bettina S. Nedergaard, Frede Donskov, Andreas Carus, Henrik Hager, Jens Randel Nyengaard, Flemming Brandt Sørensen, Jens Overgaard, Elisabeth I Penninga, Niels Graudal and Gesche Jürgens. Their work appears in journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.